Conceivable Life Sciences

Executive Summary

Conceivable Life Sciences is a private US biotechnology company developing AURA, the world's first AI-powered automated IVF laboratory. Founded in 2021 and based in San Francisco, the company aims to transform in vitro fertilization by integrating robotics, AI, machine vision, and advanced optics to automate the entire lab process. This 'single-cell surgery' platform seeks to lower costs, increase accessibility, and improve clinical outcomes compared to traditional manual IVF. By replacing human-intensive tasks with precise automation, AURA has the potential to standardize fertility treatments and scale them globally, addressing a significant unmet need in reproductive medicine. The company's technology is at the forefront of applying artificial intelligence and automation to a highly manual and variable medical field. If successful, Conceivable Life Sciences could disrupt the multibillion-dollar fertility market, making IVF more affordable and consistent. Key challenges include regulatory validation, clinical proof of safety and efficacy, and integration into existing clinic workflows. The company's early-stage status and lack of public funding data suggest a high-risk, high-reward profile. Its focus on a single transformative platform positions it as a potential leader in reproductive technology, but execution and adoption risks remain substantial.

Upcoming Catalysts (preview)

• Q3 2026Series B funding round70% success
• Q1 2027Clinical validation study results with first live births40% success
• Q4 2026Strategic partnership with a major fertility clinic network50% success